ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naline, E
Right arrow Articles by Advenier, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naline, E
Right arrow Articles by Advenier, C
Eur Respir J 1994; 7: 914-920
Copyright © ERS Journals Ltd 1994

Original Articles

Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus

E Naline, Y Zhang, Y Qian, N Mairon, GP Anderson, B Grandordy, and C Advenier

The objective of this study was to evaluate the potency and efficacy (intrinsic activity) of formoterol and salmeterol and their duration of action in comparison with other beta-adrenoceptor agonists in isolated human bronchi. Human bronchi were obtained at thoracotomy from patients with lung cancer. Potency (-log of the concentration of drug inducing 50% of maximal relaxation (-log EC50)) and efficacy (maximal effect (Emax), % of response to theophylline 3 x 10(-3) mol.l-1) were determined by analysis of cumulative isometric concentration-response curves to beta 2-adrenoceptor agonists in bronchial rings at resting tone or contracted maximally with acetylcholine 10(-3) mol.l-1 to induce functional antagonism. The onset and duration of action of beta-adrenoceptor agonists were measured by assessing the relaxant activity of drugs on the basal tone of isolated bronchi. In terms of potency, the rank order of the substances studied was formoterol > fenoterol > or = salmeterol > or = isoprenaline > or = salbutamol > or = adrenaline > or = terbutaline. Formoterol was 150-200 times more potent than isoprenaline. On preparations contracted with acetylcholine 10(-3) mol.l-1 the intrinsic activity (IA) of salbutamol, terbutaline and salmeterol compared with that of isoprenaline ranged 0.62-0.66. Intrinsic activity was higher with formoterol (0.84) and fenoterol (0.75). The onset of action of formoterol (2.14 +/- 0.55 min, n = 11) was not significantly different from that of salbutamol (1.90 +/- 0.24 min, n = 8) but shorter than that of salmeterol (6.40 +/- 1.40 min, n = 10).(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
R. G. Sturton, A. Trifilieff, A. G. Nicholson, and P. J. Barnes
Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled 2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 270 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Naline, A. Trifilieff, R. A. Fairhurst, C. Advenier, and M. Molimard
Effect of indacaterol, a novel long-acting {beta}2-agonist, on isolated human bronchi
Eur. Respir. J., March 1, 2007; 29(3): 575 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
B. Adelsberg
Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief
Evid. Based Med., October 1, 2006; 11(5): 138 - 138.
[Full Text] [PDF]

Home page
 ChestHome page
P. M. O'Byrne and E. Adelroth
{beta}2 Deja Vu
Chest, January 1, 2006; 129(1): 3 - 5.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. Lagente, E. Naline, I. Guenon, M. Corbel, E. Boichot, J.-L. Burgaud, P. Del Soldato, and C. Advenier
A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 367 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Faisy, E. Naline, J.-L. Diehl, X. Emonds-Alt, T. Chinet, and C. Advenier
In vitro sensitization of human bronchus by beta 2-adrenergic agonists
Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1033 - L1042.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. A. Nightingale, D. F. Rogers, and P. J. Barnes
Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma*
Chest, May 1, 2002; 121(5): 1401 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. Katsunuma, A. F. Roffel, C. R. S. Elzinga, J. Zaagsma, P. J. Barnes, and J. C. W. Mak
beta 2-Adrenoceptor Agonist-Induced Upregulation of Tachykinin NK2 Receptor Expression and Function in Airway Smooth Muscle
Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 409 - 417.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL
Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients
Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Teschemacher and H. Lemoine
Kinetic Analysis of Drug-Receptor Interactions of Long-Acting beta 2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl Cyclase
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1084 - 1092.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.